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Soluble or « wet » biomarkers « Dry » biomarkers
A biomarker is a characteristic that is objectively measured
and evaluated as an indicator of normal biologic processes, 
pathogenic processes, or pharmacologic responses to a 
therapeutic intervention. » 
Biomarkers Definitions Working Group I. Biomarkers and surrogate endpoints: preferred definitions
and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95.
Womac Lequesne






































Bauer et al. Osteoarthritis Cart 2006
• Biomarker associated with extent of severity of OABurden of disease
• Biomarker not yet meeting criteria for another
categoryInvestigative
• Predicts incidence of progression of disease or 
likelihood of response to a treatmentPrognostic
• Indicative of treatment efficacy and for which the 
magnitude of the change is considered pertinent to 
the response. 
Efficacy of treatment
• Dissociate diseased from non-diseased.Diagnostic
• Identify adverse effects and provide means of 
safety.oneSafety
Efficacy of intervention
« Indicative or predictive of 
treatment efficacy and for 
which the magnitude of the 
change is considered
pertinent to the response. »
Biomarkers of efficacy of treatment (BIPEDS)
Updated Van Spil et al.2010
BIPEDS Biomarkers
Efficacy of intervention uCTX-II, sColl2-1,sCOll2-1NO2, sC2C, 
sCOMP, sKS, sYLK40, sPIIANP, uNTX-
I, sOC,  sHA, sMMP-3, sCRP
« Biochemical marker concentration 
differed statistically significantly
between patient populations  with or 
without treatment, or before and 
after treatment within patient »
Levels of qualification of biomarkers for drug
development use






sC2C, sHA, NTX-1, Coll2-1, 
Coll2-1NO2
Exploratory
COMP, C1,2C, CTX-1, CS846
« To qualify for the efficacy of 
intervention category, a marker 
must demonstrate a statistically 
significant relationship between 
treatment-related changes in a 
biomarker and the clinical or 
imaging outcome” 















Richette, Roux Osteoporosis Int 2012
u CTX-II reflects
bone rather than cartilage
metabolism



























« Proof-of-concept study »
-22 knee OA patients
-2x3 caps (42 mg BOC)/days
-3 months treatment
Henrotin Y, Priem F, Mobasheri A, Springerplus, 2013
TIFLEXY Study
A proof-of-concept study
Henrotin et al., BMC Complem Altern Med,2014
Baseline 84 days of treatment p-Value
sColl2-1 (nmol/L) 302.21+/-53 257.84 +/-52.78 0.002*
sColl2-1NO2 (nmol/L) 0.71 +/- 0.78 0.80 +/- 0.24 NS
sCTX-II (ng/L) 11.81 +/-7.98 13.17+/-4.96 NS
sFib3-1 (pmol/L) 707.05 +/- 178.79 765.20 +/- 261.90 NS
sFib3-2 (pmol/L) 580.58 +/- 103.59 636.74 +/- 119.73 NS
sCRP (mg/L) 10.42 +/- 30.27 3.10 +/- 2.40 NS
sMPO (ng/ml) 27.20 +/- 29.05 21.96 +/- 14.65 NS
Time (days)


























Coll-2-1 (nmol/L) between day 0 and day 84
%










An open label observational prospective study
Conrozier et al, J Orthp Res, 2012; Henrotin et al, J Orthp Res,2013.
D1 
(after the last injection)
90 days
(after the last injection)
p-Value
D1 vs D90
sColl2-1 (nM) 140.34(882.44-285.32) 128.41 (85.6-241.34) 0.05*
sColl2-1NO2 (nM) 0.400 (0.050-1.010) 0.370 (0.14-0.870) 0.025*
uCTX-II (ng/nmolcreat) 392.7 (90.0-816.4) 306.0 (90-1123.9) 0.02*
sPIICP (ng/ml) 817.9 (131.4-1848.6) 874.8.3 (326.4-1435.0) 0.41
sC2C (ng/ml) 223.6 (99.4-329) 209.5 (135.9-291.7) 0.11
sCOMP (U/L) 10.9 (6.0-20.2) 10.5 (6.0-20.0) 0.82
sCS846 (ng/ml) 99.8 (45.9-172.3) 102.2 (53.0-190) 0.38
sHA (ng/ml) 34.1 (15.4-211) 33.3 (9.5-230.1) 0.38
 45 patients with unilateral symptomatic tibiofemoral and/or patellofemoral OA
 3-weekly intraarticular injection of hyalan G20 (Synvisc®)
 Follow-up D1, D30 and D90 after the last injection
BIOVISCO study
Other observations
Only sColl2-1 was significantly decreased 30 days after final injection
Only uCTX-II variation correlated with clinical response (walking pain decrease)
uCTX, sColl2-1 and sHA were independently predictive of clinical response








































Mean values – IC (95%)
MOVES study
CS + GuHCL (Droglican) vs Celecoxib
Preliminary data
 416 knee OA (PP)
 1200 mg CS/1500 GuHCL
 200 mg celecoxib
 6 months treatment
n AGE SEX Weight (Kg) Height (cm)
BMI 
(kg/m2)
celebrex 202 64 (9) 165/37 (82%) 78 (14) 162 (18) 30 (6)
droglican 214 62 (9) 187/27 (87%) 81 (16) 161 (18) 31 (7)
PP 416 63 (9) 352/64 (85%) 80 (15) 162 (18) 30 (6)
Both drugs decreased sColl2-1
Only Droglican decreased significantly Coll2-1









































































Mean values + IC (95%)
MOVES study
CS + GuHCL (Droglican) vs Celecoxib
P value = droglican vs celebrex
 Soluble biomarkers should be included early in the 
development of a drug : « Drug developement tool »
→ Preclinical development and phase 1-4 trials
Why?
→ to assist with selection of lead compound
→ to assess safety, mechanism of action, dose finding
and selection, dose reponse profile, enrichment of a 
target population, enrichment for progressors, post-
marketing safety surveillance
→Companion biomarker (personalized medicine)
Conclusions
Thank you for your attention !
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